RNS Number : 0262T Renalytix PLC 19 November 2021     Renalytix plc ("Renalytix" or the "Company")   Publication of Annual Report 2021 and Notice of 2021 Annual General Meeting   LONDON and SALT LAKE CITY , November 19, 2021 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual

Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans

RNS Number : 8663R Renalytix PLC 10 November 2021     Renalytix plc ("Renalytix" or the "Company")   Renalytix Convenes Expert Panel at VA Healthcare Summit   Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease   NEW

Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- St. Joseph's Health and Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to implement an

RNS Number : 7276R Renalytix PLC 09 November 2021     Renalytix plc ("Renalytix" or the "Company")   St. Joseph's Health and Renalytix Partner to Advance Value-Based Kidney Health   in New York   Partnership expands doctor and patient access to advanced prognosis and coordinated care management of

RNS Number : 9254Q Renalytix PLC 01 November 2021       Renalytix plc (" Renalytix " or the " Company ")     Issue of shares and Total Voting Rights   NEW YORK , November 1,  2021 -  Renalytix plc (AIM: RENX) announces that it has issued and allotted 68,224 ordinary shares of 0.25 pence each in the

LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based

RNS Number : 7882P Renalytix PLC 21 October 2021   Renalytix plc (" Renalytix " or the " Company ")   Renalytix Reports Full Year Fiscal 2021 Results   LONDON and SALT LAKE CITY , October 21, 2021   - Renalytix plc   (NASDAQ: RNLX),  (LSE : RENX) an artificial intelligence-enabled in vitro

LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.

RNS Number : 4032O Renalytix PLC 08 October 2021     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21   LONDON and SALT LAKE CITY , October 8, 2021 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced